Laboratory of Pharmaceutical Microbiology, Ghent University, 9000 Ghent, Belgium
David Martínez-Pérez
Biomaterials, Faculty of Materials Science and Engineering, Warsaw University of Technology, 02-507 Warsaw, Poland
Clara Guarch-Pérez
Department of Medical Microbiology and Infection Prevention, Amsterdam institute for Infection and Immunity, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, the Netherlands
Charlotte Courtens
Laboratory of Medicinal Chemistry, Ghent University, 9000 Ghent, Belgium
Andrea Sass
Laboratory of Pharmaceutical Microbiology, Ghent University, 9000 Ghent, Belgium
Emilia Choińska
Biomaterials, Faculty of Materials Science and Engineering, Warsaw University of Technology, 02-507 Warsaw, Poland
Joanna Idaszek
Biomaterials, Faculty of Materials Science and Engineering, Warsaw University of Technology, 02-507 Warsaw, Poland
Serge Van Calenbergh
Laboratory of Medicinal Chemistry, Ghent University, 9000 Ghent, Belgium
Martijn Riool
Department of Medical Microbiology and Infection Prevention, Amsterdam institute for Infection and Immunity, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, the Netherlands
Sebastian A.J. Zaat
Department of Medical Microbiology and Infection Prevention, Amsterdam institute for Infection and Immunity, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, the Netherlands
Wojciech Święszkowski
Biomaterials, Faculty of Materials Science and Engineering, Warsaw University of Technology, 02-507 Warsaw, Poland
Summary: Acinetobacter baumannii causes a wide range of infections, including wound infections. Multidrug-resistant A. baumannii is a major healthcare concern and the development of novel treatments against these infections is needed. Fosmidomycin is a repurposed antimalarial drug targeting the non-mevalonate pathway, and several derivatives show activity toward A. baumannii. We evaluated the antimicrobial activity of CC366, a fosmidomycin prodrug, against a collection of A. baumannii strains, using various in vitro and in vivo models; emphasis was placed on the evaluation of its anti-biofilm activity. We also developed a 3D-printed wound dressing containing CC366, using melt electrowriting technology. Minimal inhibitory concentrations of CC366 ranged from 1 to 64 μg/mL, and CC366 showed good biofilm inhibitory and moderate biofilm eradicating activity in vitro. CC366 successfully eluted from a 3D-printed dressing, the dressings prevented the formation of A. baumannnii wound biofilms in vitro and reduced A. baumannii infection in an in vivo mouse model.
